Get the Stockscreener App
2.04
8.93%
-0.20
Ocugen Inc stock is traded at $2.04, with a volume of 24.90M.
It is down -8.93% in the last 24 hours and up +27.50% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$2.24
Open:
$2.23
24h Volume:
24.90M
Relative Volume:
3.54
Market Cap:
$668.91M
Revenue:
$4.41M
Net Income/Loss:
$-67.85M
P/E Ratio:
-9.0345
EPS:
-0.2258
Net Cash Flow:
$-57.15M
1W Performance:
-17.74%
1M Performance:
+27.50%
6M Performance:
+52.24%
1Y Performance:
+254.17%
1-Day Range:
$2.01
$2.28
1-Week Range:
$2.01
$2.725
52-Week Range:
$0.56
$2.725
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, ALNY, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
2.04 | 668.91M | 4.41M | -67.85M | -57.15M | -0.2258 |
VRTX
Vertex Pharmaceuticals Inc
|
454.00 | 115.33B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
732.87 | 77.48B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.17 | 41.40B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
663.93 | 41.09B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
275.28 | 30.56B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Initiated | Canaccord Genuity | Buy |
| Mar-11-26 | Initiated | Oppenheimer | Outperform |
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Ocugen (NASDAQ:OCGN) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Oppenheimer initiates Ocugen (OCGN) with a buy rating - MSN
Oppenheimer Initiates Ocugen (OCGN) With a Buy Rating - Insider Monkey
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Ocugen Faces Tough Market Challenges Amidst Financial Turmoil - StocksToTrade
Canaccord initiates coverage of Ocugen, Inc. (OCGN) with a buy rating and a $12 price target - MSN
Ocugen, Inc. Files Form 8-K Current Report with SEC – Company Details, Stock Symbol, and Compliance Information - Minichart
Ocugen Stock Forecast: Weighing Cash Usage Against Advanced Trial Results - Bitget
Ocugen Stock Outlook: Balancing Cash Burn and Late-Stage Data - The Globe and Mail
Ocugen receives $15 million from warrant exercise by institutional investor By Investing.com - Investing.com
Ocugen Gains $15 Million, Extends Cash Runway to 2027 - TipRanks
Canaccord Initiates Coverage of Ocugen, Inc. (OCGN) with a Buy Rating and a $12 Price Target - Insider Monkey
Ocugen receives $15.0M from partial warrant exercise, extends cash runway into Q1 2027 - TradingView
Ocugen (NASDAQ: OCGN) raises $15M via warrant exercise, extends runway - Stock Titan
OCGN Gene-Agnostic Eye Therapy Could Shift Retinal Drug Development - TradingView
OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch - Zacks Investment Research
Oppenheimer Starts Ocugen (OCGN) at Outperform on Gene Therapy Pipeline - AOL.com
5 Best High Volume Penny Stocks to Buy Now - Insider Monkey
symbol__ Stock Quote Price and Forecast - CNN
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
Ocugen, Inc. pushes innovation in modifier gene therapies to address blindness - Traders Union
Ocugen stock surges 75% year to date: What's in store for 2026? - MSN
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
Ocugen (OCGN) Receives Buy Rating from Canaccord Genuity - GuruFocus
Ocugen a new buy at Canaccord on pipeline for retinal diseases (OCGN:NASDAQ) - Seeking Alpha
Ocugen reports 2025 results and clinical progress across gene therapy pipeline - MSN
Ocugen Q4 2025 earnings preview - MSN
Canaccord Genuity initiates coverage of Ocugen (OCGN) with buy recommendation - MSN
OCGN stock rallies on Wall Street optimism for clinical pipeline: Retail awaits new data - MSN
Ocugen Inc. stock rises Tuesday, outperforms market - MarketWatch
OCGN Stock Rallies On Wall Street Optimism For Clinical Pipeline: Retail Awaits New Data - Stocktwits
Ocugen, Inc. (NASDAQ:OCGN) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
OCGN Coverage Initiated by Canaccord Genuity with 'Buy' Rating a - GuruFocus
Canaccord Genuity Group Begins Coverage on Ocugen (NASDAQ:OCGN) - MarketBeat
Ocugen (NASDAQ:OCGN) Sets New 1-Year HighWhat's Next? - MarketBeat
Ocugen Nears Critical Data Readout for Key Eye Disease Therapy - AD HOC NEWS
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
Ocugen (NASDAQ:OCGN) Shares Down 4.6%Should You Sell? - MarketBeat
Ocugen Shares Surge Following Bullish Analyst Coverage - AD HOC NEWS
Ocugen (OCGN) Is Up 54.0% After Completing Phase 3 OCU400 Enrollment And Facing Going-Concern Warning - simplywall.st
Why Ocugen (OCGN) Is Up 54.0% After OCU400 Phase 3 Progress And Going Concern Spotlight - Yahoo Finance
Analyst Confidence Sparks Surge in Ocugen Shares - AD HOC NEWS
Ocugen Stock Jumps as Oppenheimer Initiates Outperform Rating - StocksToTrade
Ocugen’s Shares Leap 32% Post Oppenheimer’s Positive Coverage - timothysykes.com
Ocugen Inc. stock rises Friday, outperforms market - MarketWatch
Ocugen Stock Surges Amid Positive Analyst Coverage and Clinical Progress - StocksToTrade
Ocugen Stock Surges Amid Oppenheimer’s Bullish Forecast - timothysykes.com
Ocugen, Inc. (NASDAQ: OCGN) Q4 2025 earnings call transcript - MSN
Ocugen Stock Soars Following Strategic Developments in Gene Therapy Trials - timothysykes.com
Ocugen (NASDAQ:OCGN) Shares Gap UpStill a Buy? - MarketBeat
OCGN Stock Price, Quote & Chart | OCUGEN INC (NASDAQ:OCGN) - ChartMill
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):